John B. Taylor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
John B. Taylor has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Alana Hopkins
Cancer Research Horizons
2 shared publications Andrew Plant
Research Chemistry Syngenta, Jealott’s Hill International Research Centre, Berkshire RG42 6EY, U.K.
2 shared publications- Camila Pasquali
Cancer Research Horizons
2 shared publications - Charles Parry
Cancer Research Horizons
2 shared publications Duncan L. Browne
Department of Chemistry, University of Sheffield, Sheffield S3 7HF, UK
2 shared publicationsHeather McKinnon
Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K.
2 shared publications
Latest Publications
- Open Access
- 5 December 2025
- Published by Wiley
Expanding the Landscape of Covalent Drug Discovery: Irreversible Targeting of Non-Cysteine Residues
Covalent inhibitors have re-emerged as a powerful class of therapeutics due to their prolonged target engagement, ability to decouple pharmacokinetic availability from pharmacodynamic outcome, potential for high selectivity, and ability to modulate traditionally "undruggable" targets. Historically, cysteine residues have dominated covalent drug discovery owing to their unique nucleophilicity and relative scarcity in the proteome. However, the desire to broaden the chemical scope of covalent therapeutics has driven a surge of interest in irreversibly targeting other amino acid residues, such as lysine, serine, tyrosine, threonine, and histidine. This review explores the outstanding questions and challenges in developing covalent inhibitors beyond cysteine, highlighting current warhead chemistries, strategies for achieving selectivity, proteomic mapping advances, assessment of the intrinsic reactivity of the electrophiles targeting non-cysteine residues and opportunities for expanding the druggable proteome. We also discuss future directions and the biological implications of non-cysteine covalent modifications in therapeutic contexts.
- 5 December 2025
- Published by Wiley
Open AccessExpanding the Landscape of Covalent Drug Discovery: Irreversible Targeting of Non-Cysteine Residues
Covalent inhibitors have re-emerged as a powerful class of therapeutics due to their prolonged target engagement, ability to decouple pharmacokinetic availability from pharmacodynamic outcome, potential for high selectivity, and ability to modulate traditionally "undruggable" targets. Historically, cysteine residues have dominated covalent drug discovery owing to their unique nucleophilicity and relative scarcity in the proteome. However, the desire to broaden the chemical scope of covalent therapeutics has driven a surge of interest in irreversibly targeting other amino acid residues, such as lysine, serine, tyrosine, threonine, and histidine. This review explores the outstanding questions and challenges in developing covalent inhibitors beyond cysteine, highlighting current warhead chemistries, strategies for achieving selectivity, proteomic mapping advances, assessment of the intrinsic reactivity of the electrophiles targeting non-cysteine residues and opportunities for expanding the druggable proteome. We also discuss future directions and the biological implications of non-cysteine covalent modifications in therapeutic contexts.
- 31 March 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (9) , 9129-9161
Reversible Small Molecule Multivariant Ras Inhibitors Display Tunable Affinity for the Active and Inactive Forms of Ras
Activating mutations of Ras are one of the most prevalent drivers of cancer and are often associated with poor clinical outcomes. Despite FDA approval for two irreversible inhibitors that target the inactive state of KRasG12C, significant unmet clinical need still exists, and the susceptibility of non-G12C mutants to inactive-state inhibition remains unclear. Here we report the discovery of a novel series of reversible inhibitors that bind in an enlarged version of the switch I-II pocket with nanomolar affinities. Dependent on chemotype these can either preferentially bind to the inactive or active state or bind both with similar affinity. The active-state binders inhibit the Raf interaction for wild-type Ras, and a broad range of oncogenic KRas mutants with nanomolar potency. A subseries of these molecules displays cellular inhibition of Ras-Raf binding, as well as decreased phosphorylation of the downstream protein ERK, demonstrating that potent multivariant Ras inhibitors can be accessed from this novel pocket.
- 31 March 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (9) , 9129-9161
Reversible Small Molecule Multivariant Ras Inhibitors Display Tunable Affinity for the Active and Inactive Forms of Ras
Activating mutations of Ras are one of the most prevalent drivers of cancer and are often associated with poor clinical outcomes. Despite FDA approval for two irreversible inhibitors that target the inactive state of KRasG12C, significant unmet clinical need still exists, and the susceptibility of non-G12C mutants to inactive-state inhibition remains unclear. Here we report the discovery of a novel series of reversible inhibitors that bind in an enlarged version of the switch I-II pocket with nanomolar affinities. Dependent on chemotype these can either preferentially bind to the inactive or active state or bind both with similar affinity. The active-state binders inhibit the Raf interaction for wild-type Ras, and a broad range of oncogenic KRas mutants with nanomolar potency. A subseries of these molecules displays cellular inhibition of Ras-Raf binding, as well as decreased phosphorylation of the downstream protein ERK, demonstrating that potent multivariant Ras inhibitors can be accessed from this novel pocket.
- Open Access
- 13 November 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Reversible Small Molecule pan-Ras Inhibitors Display Tunable Affinity for the Active and Inactive forms of Ras.
Activating mutations of Ras are one of the most prevalent drivers of cancer and are often associated with poor clinical outcomes. Despite FDA approval for two irreversible inhibitors that target the inactive state of KRasG12C, significant unmet clinical need still exists, and the susceptibility of non-G12C mutants to inactive-state inhibition remains unclear. Here we report the discovery of a novel series of reversible inhibitors that bind in an enlarged version of the switch I-II pocket with nanomolar affinities. Dependent on chemotype these can either preferentially bind to the inactive or active state or bind both with similar affinity. The active-state binders inhibit the Raf interaction for wild-type Ras, and a broad range of oncogenic KRas mutants with nanomolar potency. A sub-series of these molecules displays cellular inhibition of Ras-Raf binding, as well as decreased phosphorylation of the downstream protein ERK, demonstrating that potent pan-Ras inhibitors can be accessed from this novel pocket.
- 13 November 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessReversible Small Molecule pan-Ras Inhibitors Display Tunable Affinity for the Active and Inactive forms of Ras.
Activating mutations of Ras are one of the most prevalent drivers of cancer and are often associated with poor clinical outcomes. Despite FDA approval for two irreversible inhibitors that target the inactive state of KRasG12C, significant unmet clinical need still exists, and the susceptibility of non-G12C mutants to inactive-state inhibition remains unclear. Here we report the discovery of a novel series of reversible inhibitors that bind in an enlarged version of the switch I-II pocket with nanomolar affinities. Dependent on chemotype these can either preferentially bind to the inactive or active state or bind both with similar affinity. The active-state binders inhibit the Raf interaction for wild-type Ras, and a broad range of oncogenic KRas mutants with nanomolar potency. A sub-series of these molecules displays cellular inhibition of Ras-Raf binding, as well as decreased phosphorylation of the downstream protein ERK, demonstrating that potent pan-Ras inhibitors can be accessed from this novel pocket.
- Open Access
- 1 December 2018
- Published by American Psychiatric Association Publishing in Psychiatric Services
- Vol. 69 (12) , 1230-1237
Behavioral Health Factors as Predictors of Emergency Department Use in the High-Risk, High-Cost Medicare Population
This study measured the presence, extent, and type of behavioral health factors in a high-cost Medicare population and their association with the probability and intensity of emergency department (ED) use. Retrospective claims analysis and a comprehensive electronic medical record-based review were conducted for patients enrolled in a 65-month prospective care management program at an academic tertiary medical center (N=3,620). A two-part model used multivariable logistic regression to evaluate the effect of behavioral health factors on the probability of ED use, complemented by a Poisson model to measure the number of ED visits. Control variables included demographic characteristics, poststudy survival, and hierarchical condition category risk score. After analyses controlled for comorbidities and other relevant variables, patients with two or more behavioral health diagnosis categories or two or more behavioral health medications were about twice as likely as those without such categories or medications to use the ED. Patients with a diagnosis category of psychosis, neuropsychiatric disorders, sleep disorders, or adjustment disorders were significantly more likely than those without these disorders to use the ED. Most primary ED diagnoses were not of behavioral health conditions. Behavioral health factors had a substantial and significant effect on the likelihood and number of ED visits in a population of high-cost Medicare patients. Attention to behavioral health factors as independent predictors of ED use may be useful in influencing ED use in high-cost populations.
- 1 December 2018
- Published by American Psychiatric Association Publishing in Psychiatric Services
- Vol. 69 (12) , 1230-1237
Open AccessBehavioral Health Factors as Predictors of Emergency Department Use in the High-Risk, High-Cost Medicare Population
This study measured the presence, extent, and type of behavioral health factors in a high-cost Medicare population and their association with the probability and intensity of emergency department (ED) use. Retrospective claims analysis and a comprehensive electronic medical record-based review were conducted for patients enrolled in a 65-month prospective care management program at an academic tertiary medical center (N=3,620). A two-part model used multivariable logistic regression to evaluate the effect of behavioral health factors on the probability of ED use, complemented by a Poisson model to measure the number of ED visits. Control variables included demographic characteristics, poststudy survival, and hierarchical condition category risk score. After analyses controlled for comorbidities and other relevant variables, patients with two or more behavioral health diagnosis categories or two or more behavioral health medications were about twice as likely as those without such categories or medications to use the ED. Patients with a diagnosis category of psychosis, neuropsychiatric disorders, sleep disorders, or adjustment disorders were significantly more likely than those without these disorders to use the ED. Most primary ED diagnoses were not of behavioral health conditions. Behavioral health factors had a substantial and significant effect on the likelihood and number of ED visits in a population of high-cost Medicare patients. Attention to behavioral health factors as independent predictors of ED use may be useful in influencing ED use in high-cost populations.
- Open Access
- 17 May 2013
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 49 (57) , 6385-6387
Silver-catalysed trifluoromethylation of arenes at room temperature
Silver catalysis is effective for the trifluoromethylation of heteroarenes, electron rich aromatics and functionalised agrochemicals using TMSCF 3 .
- 17 May 2013
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 49 (57) , 6385-6387
Open AccessSilver-catalysed trifluoromethylation of arenes at room temperature
Silver catalysis is effective for the trifluoromethylation of heteroarenes, electron rich aromatics and functionalised agrochemicals using TMSCF 3 .
- 25 April 2013
- Published by Elsevier in Tetrahedron Letters
- Vol. 54 (26) , 3378-3383
Synthesis of novel heterocyclic acetyl coenzyme-A carboxylase inhibitors via a Claisen rearrangement
- 25 April 2013
- Published by Elsevier in Tetrahedron Letters
- Vol. 54 (26) , 3378-3383
Synthesis of novel heterocyclic acetyl coenzyme-A carboxylase inhibitors via a Claisen rearrangement
- 29 May 2012
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 48 (66) , 8270-8272
Protodecarboxylation of benzoic acids under radical conditions
A new approach to protodecarboxylation is described that enhances the substrate scope for benzoic acids. The reaction uses oxidative radical conditions to decarboxylate a variety of acids in acetonitrile.
- 29 May 2012
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 48 (66) , 8270-8272
Protodecarboxylation of benzoic acids under radical conditions
A new approach to protodecarboxylation is described that enhances the substrate scope for benzoic acids. The reaction uses oxidative radical conditions to decarboxylate a variety of acids in acetonitrile.
- 23 December 2009
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 75 (3) , 984-987
Alkyne [3 + 2] Cycloadditions of Iodosydnones Toward Functionalized 1,3,5-Trisubstituted Pyrazoles
The cycloaddition of 4-iodosydnones with terminal alkynes proceeds with excellent regiocontrol to provide 5-iodo pyrazoles. These products participate smoothly in subsequent C−C and C−heteroatom bond forming processes.
- 23 December 2009
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 75 (3) , 984-987
Alkyne [3 + 2] Cycloadditions of Iodosydnones Toward Functionalized 1,3,5-Trisubstituted Pyrazoles
The cycloaddition of 4-iodosydnones with terminal alkynes proceeds with excellent regiocontrol to provide 5-iodo pyrazoles. These products participate smoothly in subsequent C−C and C−heteroatom bond forming processes.
- 16 November 2008
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 74 (1) , 396-400
Cross Coupling of Bromo Sydnones: Development of a Flexible Route toward Functionalized Pyrazoles
The application of a Suzuki cross coupling approach to a range of C-4 substituted sydnones from a 4-bromosydnone is described. Moreover, the potential of this approach to prepare a diverse range of pyrazoles is demonstrated.
- 16 November 2008
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 74 (1) , 396-400
Cross Coupling of Bromo Sydnones: Development of a Flexible Route toward Functionalized Pyrazoles
The application of a Suzuki cross coupling approach to a range of C-4 substituted sydnones from a 4-bromosydnone is described. Moreover, the potential of this approach to prepare a diverse range of pyrazoles is demonstrated.